Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Core Insights - Neuphoria Therapeutics Inc. is nearing the topline data release from its AFFIRM-1 Phase 3 trial of BNC-210 for social anxiety disorder (SAD), expected in early Q4 2025, which is a significant milestone for the company [1][3][10] - The company has extended its cash runway through fiscal Q2 2027, with a cash position of $14.2 million as of June 30, 2025 [5][10] Clinical Program Highlights - BNC-210 is an oral, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, being developed for SAD and PTSD, and has received FDA Fast Track designation [8][9] - The drug has shown rapid-onset and meaningful anti-anxiety effects in previous clinical trials without sedation or cognitive impairment [8][11] Financial Results - For the fiscal year ended June 30, 2025, Neuphoria reported a net loss of $0.4 million, significantly reduced from a net loss of $15.5 million in the previous year [7][18] - Research and development expenses decreased to $9.0 million from $9.4 million year-over-year, while general and administrative expenses also saw a decline from $8.5 million to $7.8 million [6][7] - The company generated $15.6 million in license revenue for the fiscal year 2025, compared to no revenue in 2024 [17] Strategic Partnerships and Future Plans - Neuphoria is collaborating with Merck & Co., Inc. on two positive allosteric modulator candidates for Alzheimer's disease, with one currently in a Phase 2 trial [10][11] - The company plans to initiate the SYMPHONY Phase 2b/3 trial for PTSD in the first half of 2026 [10]